CTOs on the Move

Checkmate Pharmaceuticals

www.checkmatepharma.com

 
Checkmate Pharmaceuticals is a clinical stage biotechnology company focused on developing its proprietary technology to harness the power of the immune system to combat cancer. Checkmate`s product candidate, CMP-001, is an advanced generation TLR9 agonist delivered as a biologic virus-like particle designed to trigger the body`s innate immune system to attack tumors in combination with other therapies.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details

Funding

Checkmate Pharmaceuticals raised $20M on 08/12/2015
Checkmate Pharmaceuticals raised $27M on 06/15/2017
Checkmate Pharmaceuticals raised $22M on 12/12/2018
Checkmate Pharmaceuticals raised $15.9M on 01/27/2020
Checkmate Pharmaceuticals raised $85M on 06/10/2020

Similar Companies

Denton County MHMR Center

Denton County MHMR Center mission is to enhance the quality of life of the individuals served and their family members. Crisis Line 24/7: 1-800-762-0157

Artelon

Artelons technology was developed explicitly to enhance the strength and kinematic demands of reconstructed tendons and ligaments. Artelons Dynamic Matrix restores native motion, resists the necrotic degradation of  strength, and promotes an ideal me...

Vascular Technology

Vascular Technology Incorporated is a Nashua, NH-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Development Chemicals

Development Chemicals is a Atlantic Highlands, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Elevar Therapeutics

Elevar Therapeutics is a rapidly growing, fully integrated biopharmaceutical company built on the promise of elevating treatment experiences and outcomes for patients who have limited or inadequate therapeutic options. Elevar`s lead proprietary drug candidates include rivoceranib (apatinib) and Apealea® (paclitaxel micellar). Rivoceranib is the first small-molecule tyrosine kinase inhibitor (TKI) to be approved in gastric cancer (China, Dec 2014). It has been granted Orphan Drug designation in the U.S., Europe and South Korea and has been clinically tested in over 1,000 patients worldwide in numerous cancer indications. Apealea® (paclitaxel micellar) is a non-Cremophor EL based formulation of paclitaxel that received marketing authorization by the European Commission in November 2018, making it Europe`s first non-Cremophor EL formulation of paclitaxel approved for use in ovarian cancer. Elevar Therapeutics has offices in Utah, California and South Korea.